Cargando…

The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All

Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structur...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoreński, Marcin, Sieńczyk, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622370/
https://www.ncbi.nlm.nih.gov/pubmed/34832946
http://dx.doi.org/10.3390/ph14111164
_version_ 1784605677798293504
author Skoreński, Marcin
Sieńczyk, Marcin
author_facet Skoreński, Marcin
Sieńczyk, Marcin
author_sort Skoreński, Marcin
collection PubMed
description Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents.
format Online
Article
Text
id pubmed-8622370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86223702021-11-27 The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All Skoreński, Marcin Sieńczyk, Marcin Pharmaceuticals (Basel) Review Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents. MDPI 2021-11-16 /pmc/articles/PMC8622370/ /pubmed/34832946 http://dx.doi.org/10.3390/ph14111164 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Skoreński, Marcin
Sieńczyk, Marcin
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_full The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_fullStr The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_full_unstemmed The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_short The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_sort fellowship of privileged scaffolds—one structure to inhibit them all
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622370/
https://www.ncbi.nlm.nih.gov/pubmed/34832946
http://dx.doi.org/10.3390/ph14111164
work_keys_str_mv AT skorenskimarcin thefellowshipofprivilegedscaffoldsonestructuretoinhibitthemall
AT sienczykmarcin thefellowshipofprivilegedscaffoldsonestructuretoinhibitthemall
AT skorenskimarcin fellowshipofprivilegedscaffoldsonestructuretoinhibitthemall
AT sienczykmarcin fellowshipofprivilegedscaffoldsonestructuretoinhibitthemall